Ultragenyx Pharmaceutical
RARE· Manufacturing· Fiscal year ends in December
Emil D. Kakkis, M.D., Ph.D. is the CEO of Ultragenyx Pharmaceutical and was paid $11.4M in FY2025 (Dec), down 17%.
Executives5
See all- 1Emil D. Kakkis, M.D., Ph.D.President and Chief Executive OfficerFY2025
- 2Erik HarrisChief Commercial Officer and Executive Vice PresidentFY2025
- 3Eric Crombez, M.D.Chief Medical Officer and Executive Vice PresidentFY2025
- 4Howard HornChief Financial Officer, Corporate Strategy and Executive Vice PresidentFY2025
- 5Karah ParschauerChief Legal Officer and Corporate Affairs, Executive Vice PresidentFY2025
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allUltragenyx Pharmaceutical paid its 5 named executives $26.7M in total in FY2025 (Dec). CEO Emil D. Kakkis, M.D., Ph.D. was paid $11.4M of that.
| Name | |||
|---|---|---|---|
| Emil D. Kakkis, M.D., Ph.D.President and Chief Executive Officer | |||
| Erik HarrisChief Commercial Officer and Executive Vice President | |||
| Eric Crombez, M.D.Chief Medical Officer and Executive Vice President | Not disclosed | ||
| Howard HornChief Financial Officer, Corporate Strategy and Executive Vice President | |||
| Karah ParschauerChief Legal Officer and Corporate Affairs, Executive Vice President | Not disclosed |
of each named executive, from the Summary Compensation Table of each proxy.
Peers19
See allThe FY2025 (Dec) proxy of Ultragenyx Pharmaceutical names 19 peer companies for pay. Among Ultragenyx Pharmaceutical and these peers, CEO pay was 7th highest of 9 and total shareholder return was the lowest of 9.
7th highest of 9in Ultragenyx Pharmaceutical and its pay peers, FY2025 (Dec) by CEO pay:
9th highest of 9in Ultragenyx Pharmaceutical and its pay peers, FY2025 (Dec) by total shareholder return:
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.
Activity
Filings6
See all| Proxy statement | DEF 14A | Mar 27, 2026 | FY2025 |
| Annual report | 10-K | Feb 18, 2026 | FY2025 |
| Proxy statement | DEF 14A | Mar 28, 2025 | FY2024 |
| Annual report | 10-K | Feb 19, 2025 | FY2024 |
| Proxy statement | DEF 14A | Apr 26, 2024 | FY2023 |
| Annual report | 10-K | Feb 21, 2024 | FY2023 |